Holen Sie sich die Stockscreener-App
56.75
3.78%
-2.23
Handel nachbörslich:
57.20
0.45
+0.79%
Schlusskurs vom Vortag:
$58.98
Offen:
$58.91
24-Stunden-Volumen:
2.35M
Relative Volume:
1.10
Marktkapitalisierung:
$10.90B
Einnahmen:
$2.95B
Nettoeinkommen (Verlust:
$523.88M
KGV:
21.10
EPS:
2.69
Netto-Cashflow:
$620.18M
1W Leistung:
-1.61%
1M Leistung:
-5.90%
6M Leistung:
-19.51%
1J Leistung:
-36.85%
1-Tages-Spanne:
$55.99
$58.91
1-Wochen-Bereich:
$55.99
$59.79
52-Wochen-Spanne:
$52.93
$90.01
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
56.75 | 11.35B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-02-24 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-30 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
What Does Wall Street Think About BioMarin Pharmaceutical (BMRN)? - MSN
BioMarin (BMRN) Down 4.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
BioMarin’s Strategic Position in the 2025 Healthcare Innovation Landscape - AInvest
Will BioMarin Pharmaceutical Inc. outperform small cap indexesPortfolio Update Report & Stock Market Timing Techniques - khodrobank.com
Can you recover from losses in BioMarin Pharmaceutical Inc.2025 AllTime Highs & Safe Capital Growth Trade Ideas - Newser
What makes BioMarin Pharmaceutical Inc. stock price move sharplyQuarterly Profit Review & Entry Point Confirmation Signals - Newser
Intraday pattern recognizer results for BioMarin Pharmaceutical Inc.2025 Top Decliners & Verified Swing Trading Watchlist - Newser
Technical signs of recovery in BioMarin Pharmaceutical Inc.Long Setup & Fast Gain Swing Trade Alerts - Newser
BioMarin Pharmaceutical Inc. stock daily chart insightsWeekly Market Outlook & Fast Exit and Entry Trade Guides - Newser
Analyzing drawdowns of BioMarin Pharmaceutical Inc. with statistical toolsPortfolio Profit Report & Stock Market Timing Techniques - Newser
Is BioMarin Pharmaceutical Inc. stock influenced by commodity pricesQuarterly Market Summary & Expert Approved Trade Ideas - khodrobank.com
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed? - 富途牛牛
Should I invest in BioMarin Pharmaceutical Inc. before earningsTrade Risk Assessment & AI Forecast Swing Trade Picks - khodrobank.com
Combining price and volume data for BioMarin Pharmaceutical Inc.Weekly Trend Summary & Risk Managed Investment Strategies - Newser
Applying Wyckoff theory to BioMarin Pharmaceutical Inc. stockWeekly Gains Report & Real-Time Market Sentiment Alerts - Newser
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - au.finance.yahoo.com
Should you wait for a breakout in BioMarin Pharmaceutical Inc.Trade Analysis Summary & AI Optimized Trade Strategies - Newser
Can you recover from losses in BioMarin Pharmaceutical IncJuly 2025 Volume & Real-Time Stock Price Movement Reports - Newser
What moving averages say about BioMarin Pharmaceutical Inc.2025 Bull vs Bear & Expert-Curated Trade Recommendations - Newser
Will BioMarin Pharmaceutical Inc. bounce back from current supportJuly 2025 Price Swings & High Conviction Trade Alerts - Newser
Identifying reversal signals in BioMarin Pharmaceutical Inc.July 2025 Institutional & Weekly Top Performers Watchlists - Newser
Top chart patterns to watch in BioMarin Pharmaceutical Inc.Earnings Miss & Real-Time Volume Trigger Notifications - Newser
How to use a screener to detect BioMarin Pharmaceutical Inc. breakoutsWeekly Profit Report & Fast Moving Market Watchlists - Newser
Will BioMarin Pharmaceutical Inc. price bounce be sustainable2025 Support & Resistance & Reliable Breakout Forecasts - Newser
Tick level data insight on BioMarin Pharmaceutical Inc. volatility2025 Year in Review & Fast Entry High Yield Stock Tips - Newser
Is BioMarin Pharmaceutical Inc. stock poised for growthMarket Growth Summary & Weekly Setup with High ROI Potential - Newser
Elliott Wave Theory Predicts Pullback in BioMarin Pharmaceutical Inc. getLinesFromResByArray error: size == 0 - thegnnews.com
Should I set a stop loss on BioMarin Pharmaceutical Inc.July 2025 Sector Moves & Free Reliable Trade Execution Plans - sundaytimes.kr
Technical signs of recovery in BioMarin Pharmaceutical IncMarket Sentiment Review & Weekly Consistent Profit Watchlists - Newser
Bernstein Maintains a Buy Rating on BioMarin Pharmaceutical (BMRN) - MSN
Watch for Bullish Crossover in BioMarin Pharmaceutical Inc. getLinesFromResByArray error: size == 0 - kangso.co.kr
Visual trend scoring systems applied to BioMarin Pharmaceutical Inc.Earnings Trend Report & Expert Approved Momentum Ideas - Newser
Reversal indicators forming on BioMarin Pharmaceutical Inc. stockLong Setup & AI Enhanced Trade Execution Alerts - Newser
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):